These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
249 related articles for article (PubMed ID: 21420486)
1. IL-27 mediates the response to IFN-β therapy in multiple sclerosis patients by inhibiting Th17 cells. Sweeney CM; Lonergan R; Basdeo SA; Kinsella K; Dungan LS; Higgins SC; Kelly PJ; Costelloe L; Tubridy N; Mills KH; Fletcher JM Brain Behav Immun; 2011 Aug; 25(6):1170-81. PubMed ID: 21420486 [TBL] [Abstract][Full Text] [Related]
2. T helper type 1 and 17 cells determine efficacy of interferon-beta in multiple sclerosis and experimental encephalomyelitis. Axtell RC; de Jong BA; Boniface K; van der Voort LF; Bhat R; De Sarno P; Naves R; Han M; Zhong F; Castellanos JG; Mair R; Christakos A; Kolkowitz I; Katz L; Killestein J; Polman CH; de Waal Malefyt R; Steinman L; Raman C Nat Med; 2010 Apr; 16(4):406-12. PubMed ID: 20348925 [TBL] [Abstract][Full Text] [Related]
3. IFN-β regulates Th17 differentiation partly through the inhibition of osteopontin in experimental autoimmune encephalomyelitis. Zhao Q; Cheng W; Xi Y; Cao Z; Xu Y; Wu T; Li C; Niu X; Chen G Mol Immunol; 2018 Jan; 93():20-30. PubMed ID: 29127843 [TBL] [Abstract][Full Text] [Related]
4. IFN-beta inhibits human Th17 cell differentiation. Ramgolam VS; Sha Y; Jin J; Zhang X; Markovic-Plese S J Immunol; 2009 Oct; 183(8):5418-27. PubMed ID: 19783688 [TBL] [Abstract][Full Text] [Related]
6. Interferon beta inhibits the Th17 cell-mediated autoimmune response in patients with relapsing-remitting multiple sclerosis. Zhang X; Markovic-Plese S Clin Neurol Neurosurg; 2010 Sep; 112(7):641-5. PubMed ID: 20570038 [TBL] [Abstract][Full Text] [Related]
7. Independent and interdependent immunoregulatory effects of IL-27, IFN-β, and IL-10 in the suppression of human Th17 cells and murine experimental autoimmune encephalomyelitis. Fitzgerald DC; Fonseca-Kelly Z; Cullimore ML; Safabakhsh P; Saris CJ; Zhang GX; Rostami A J Immunol; 2013 Apr; 190(7):3225-34. PubMed ID: 23455508 [TBL] [Abstract][Full Text] [Related]
8. Comparison of Expression Levels of miR-29b-3p and miR-326 in T Helper-1 and T Helper-17 Cells Isolated from Responsive and Non-responsive Relapsing-remitting Multiple Sclerosis Patients Treated with Interferon-beta. Karimi L; Eskandari N; Shaygannejad V; Zare N; Andalib A; Khanahmad H; Mirmosayyeb O Iran J Allergy Asthma Immunol; 2020 Aug; 19(4):416-425. PubMed ID: 33463108 [TBL] [Abstract][Full Text] [Related]
9. Time-dependent cytokine deviation toward the Th2 side in Japanese multiple sclerosis patients with interferon beta-1b. Ochi H; Feng-Jun M; Osoegawa M; Minohara M; Murai H; Taniwaki T; Kira J J Neurol Sci; 2004 Jul; 222(1-2):65-73. PubMed ID: 15240198 [TBL] [Abstract][Full Text] [Related]
10. Th22 cells are expanded in multiple sclerosis and are resistant to IFN-β. Rolla S; Bardina V; De Mercanti S; Quaglino P; De Palma R; Gned D; Brusa D; Durelli L; Novelli F; Clerico M J Leukoc Biol; 2014 Dec; 96(6):1155-64. PubMed ID: 25097195 [TBL] [Abstract][Full Text] [Related]
11. Regulatory effects of IFN-beta on production of osteopontin and IL-17 by CD4+ T Cells in MS. Chen M; Chen G; Nie H; Zhang X; Niu X; Zang YC; Skinner SM; Zhang JZ; Killian JM; Hong J Eur J Immunol; 2009 Sep; 39(9):2525-36. PubMed ID: 19670379 [TBL] [Abstract][Full Text] [Related]
12. The role of endogenous IFN-β in the regulation of Th17 responses in patients with relapsing-remitting multiple sclerosis. Tao Y; Zhang X; Chopra M; Kim MJ; Buch KR; Kong D; Jin J; Tang Y; Zhu H; Jewells V; Markovic-Plese S J Immunol; 2014 Jun; 192(12):5610-7. PubMed ID: 24850724 [TBL] [Abstract][Full Text] [Related]
13. Evaluation of Th17-related cytokines and receptors in multiple sclerosis patients under interferon β-1 therapy. Esendagli G; Kurne AT; Sayat G; Kilic AK; Guc D; Karabudak R J Neuroimmunol; 2013 Feb; 255(1-2):81-4. PubMed ID: 23177721 [TBL] [Abstract][Full Text] [Related]
14. Interferon-beta inhibits Th17 cell differentiation in patients with multiple sclerosis. Ramgolam VS; Markovic-Plese S Endocr Metab Immune Disord Drug Targets; 2010 Jun; 10(2):161-7. PubMed ID: 20384573 [TBL] [Abstract][Full Text] [Related]
15. Simvastatin inhibits IFN regulatory factor 4 expression and Th17 cell differentiation in CD4+ T cells derived from patients with multiple sclerosis. Zhang X; Tao Y; Troiani L; Markovic-Plese S J Immunol; 2011 Sep; 187(6):3431-7. PubMed ID: 21856936 [TBL] [Abstract][Full Text] [Related]
16. Cytokines and disability in interferon-β-1b treated and untreated women with multiple sclerosis. Trenova AG; Slavov GS; Manova MG; Kostadinova II Arch Med Res; 2014 Aug; 45(6):495-500. PubMed ID: 25130430 [TBL] [Abstract][Full Text] [Related]
17. B cells as a therapeutic target for IFN-β in relapsing-remitting multiple sclerosis. Ramgolam VS; Sha Y; Marcus KL; Choudhary N; Troiani L; Chopra M; Markovic-Plese S J Immunol; 2011 Apr; 186(7):4518-26. PubMed ID: 21368231 [TBL] [Abstract][Full Text] [Related]
18. Interferon-β regulates dendritic cell activation and migration in experimental autoimmune encephalomyelitis. Pennell LM; Fish EN Immunology; 2017 Nov; 152(3):439-450. PubMed ID: 28646573 [TBL] [Abstract][Full Text] [Related]
19. Betaine Ameliorates Experimental Autoimmune Encephalomyelitis by Inhibiting Dendritic Cell-Derived IL-6 Production and Th17 Differentiation. Yang C; Lai W; Zhou J; Zheng X; Cai Y; Yang W; Xie S; Gao Y; Du C J Immunol; 2018 Feb; 200(4):1316-1324. PubMed ID: 29330324 [TBL] [Abstract][Full Text] [Related]
20. Simvastatin inhibits secretion of Th17-polarizing cytokines and antigen presentation by DCs in patients with relapsing remitting multiple sclerosis. Zhang X; Tao Y; Wang J; Garcia-Mata R; Markovic-Plese S Eur J Immunol; 2013 Jan; 43(1):281-9. PubMed ID: 23076801 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]